Overview

• Hyperfine Q3 2025 revenue rises 27% from Q2, reaching $3.4 mln

• Company reports Q3 net loss of $11 mln, or $0.14 per share

• Raised $20.1 mln in gross proceeds through an underwritten public offering in October 2025 to support growth and expansion

Outlook

• Hyperfine expects Q4 2025 revenue between $5 mln and $6 mln

• Full-year 2025 revenue expected to be $13 mln to $14 mln

• Company forecasts 2025 cash burn of $29 mln to $31 mln

Result Drivers

• NEXT GENERATION SWOOP LAUNCH - Co launched next gen Swoop system with Optive AI, driving adoption across multiple care sites

• NEUROLOGY OFFICE EXPANSION - Co initiated commercial launch in neurology offices, creating new revenue opportunities

• U.S. HOSPITAL PIPELINE CONVERSION - Co converted entire U.S. hospital pipeline to next gen Swoop system

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

• Wall Street's median 12-month price target for Hyperfine Inc is $1.70, about 35.3% above its November 12 closing price of $1.10

Press Release: ID:nBw87gL34a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)